Cullinan Therapeutics (NASDAQ:CGEM) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cullinan Therapeutics (NASDAQ:CGEM) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $28.00 target price on the stock.

Separately, Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, September 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cullinan Therapeutics has an average rating of “Buy” and a consensus target price of $32.00.

Cullinan Therapeutics Stock Performance

Shares of NASDAQ:CGEM opened at $16.77 on Wednesday. The company has a market capitalization of $966.52 million, a P/E ratio of -5.36 and a beta of -0.13. The company’s 50-day moving average is $17.35 and its 200 day moving average is $19.22. Cullinan Therapeutics has a fifty-two week low of $7.64 and a fifty-two week high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, August 8th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). As a group, research analysts predict that Cullinan Therapeutics will post -3.2 earnings per share for the current year.

Insider Activity at Cullinan Therapeutics

In related news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $18.09, for a total value of $144,720.00. Following the completion of the transaction, the insider now directly owns 115,942 shares in the company, valued at approximately $2,097,390.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.07% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of large investors have recently made changes to their positions in CGEM. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Cullinan Therapeutics by 22.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,269 shares of the company’s stock valued at $294,000 after purchasing an additional 3,134 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Cullinan Therapeutics by 31.0% during the first quarter. Ameritas Investment Partners Inc. now owns 2,599 shares of the company’s stock valued at $44,000 after buying an additional 615 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Cullinan Therapeutics by 3.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,842 shares of the company’s stock worth $390,000 after buying an additional 820 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Cullinan Therapeutics by 39.4% in the second quarter. Harbor Capital Advisors Inc. now owns 17,481 shares of the company’s stock valued at $305,000 after acquiring an additional 4,941 shares during the period. Finally, SG Americas Securities LLC grew its stake in Cullinan Therapeutics by 757.2% during the second quarter. SG Americas Securities LLC now owns 85,172 shares of the company’s stock valued at $1,485,000 after acquiring an additional 75,236 shares in the last quarter. 86.31% of the stock is owned by institutional investors.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.